SPDR S&P Biotech ETF
123 hedge funds and large institutions have $1.6B invested in SPDR S&P Biotech ETF in 2014 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 26 increasing their positions, 56 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
54% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 56
78% less call options, than puts
Call options by funds: $10.7M | Put options by funds: $48.9M
Holders
123
Holding in Top 10
2
Calls
$10.7M
Puts
$48.9M
Top Buyers
| 1 | +$110M | |
| 2 | +$43.5M | |
| 3 | +$20.4M | |
| 4 |
Barclays
London,
United Kingdom
|
+$15.4M |
| 5 |
Morgan Stanley
New York
|
+$10.8M |
Top Sellers
| 1 | -$111M | |
| 2 | -$67.8M | |
| 3 | -$42.6M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$26M |
| 5 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$18.9M |